Chinese FDA is performing more international Inspections
Recommendation
27/28 May 2025
Supervision of the Pharmaceutical Quality System: Challenges and Opportunities
Register now for ECA's GMP Newsletter
The China Food and Drug Administration (CFDA) has published its "Annual Report of Drug Inspection 2016". This report mainly lists summarised results of inspections performed by CFDA in China. But in Part V of the report, an overview is given on international inspection activities:
The total number of CFDA overseas inspections performed last year was 49 inspections in 19 countries. A number which has been constantly growing over the last years:
Most of these inspections (33) were performed in Europe. Six were performed in North America. Countries like Vietnam and India are called "countries with high regional quality risks" in the report. However, only one Indian company was inspected.
Overall, 40 different products ("chemicals") were covered in the inspections, including "injections, solid preparations, implants and nasal sprays".
Most observations were made in Quality Control and Quality Assurance (22 with 6 major deficiencies), Material System and Change Management. Serious deficiencies were mainly noted as "problems in the consistency of production process and data integrity". Deficiencies in local inspections were mainly observed in the areas of Quality Control and Quality Assurance and Documentation Management.
Source: CFDA Annual Report of Drug Inspection 2016
Related GMP News
30.04.2025QP Declaration: New Q&As published
19.03.2025Root Cause Analysis: Again, problems discovered in GMP-Inspections
19.03.2025ICMRA publishes Hybrid Inspection Pilot Summary Report
19.03.2025From Burkholderia to Ethylene Glycol - a List of Deficiencies at a Manufacturer of OTC Products
19.03.2025Warning Letter - Deficiencies in the Control of Raw and Starting Materials
19.03.2025Inadequate Microbiological Testing of Nonsterile Products - FDA Warning Letter